Aprea Therapeutics (NASDAQ:APRE) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its quarterly earnings data on Monday. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05, Yahoo Finance reports. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%.

Aprea Therapeutics Stock Performance

Shares of Aprea Therapeutics stock traded down $0.05 during trading on Wednesday, hitting $3.25. 11,011 shares of the stock were exchanged, compared to its average volume of 19,875. Aprea Therapeutics has a 12 month low of $3.20 and a 12 month high of $8.85. The stock has a market cap of $17.65 million, a PE ratio of -0.98 and a beta of 1.04. The stock’s fifty day moving average is $3.95 and its 200 day moving average is $5.26.

Analyst Ratings Changes

APRE has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Monday. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.